登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，5月15日，Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-16

  • Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level

    Frederick J. Angulo, DVM, PhD1; Lyn Finelli, DrPH, MS2; David L. Swerdlow, MD1

    Author Affiliations Article Information

    JAMA. Published online May 15, 2020. doi:10.1001/jama.2020.7872

    Through May 13, 2020, approximately 1.39 million cases of coronavirus disease 2019 (COVID-19) have been reported in the United States (by the Centers for Disease Control and Prevention) and more than 4.3 million cases of COVID-19 have been reported from 188 countries.1 There is an urgent need for COVID-19 data, including community-level incidence, spectrum of disease, diagnostic test penetration, and proportion of the community with protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (herd immunity). These data are vital to understanding where communities are on the continuum of COVID-19 cumulative incidence and prevalence and how nonpharmaceutical interventions can be titrated to reopen business and society. Real-time incidence and seroepidemiologic data are also essential to plan scenarios for the development of COVID-19 vaccines and therapeutics. Cross-sectional community surveys combined with seroepidemiology can help inform the present and help navigate the path forward.

  • 原文来源：https://jamanetwork.com/journals/jama/fullarticle/2766293
32浏览量
原文链接
相关报告

  • 《Science，5月5日，Rapid implementation of mobile technology for real-time epidemiology of COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-06
    • Rapid implementation of mobile technology for real-time epidemiology of COVID-19 David A. Drew1,*, Long H. Nguyen1,*, Claire J. Steves2,3, Cristina Menni2, Maxim Freydin2, Thomas Varsavsky4, Carole H. Sudre4, M. Jorge Cardoso4, Sebastien Ourselin4, Jonathan Wolf5, Tim D. Spector2,5,†, Andrew T. Chan1,6,†,‡, COPE Consortium§ See all authors and affiliations Science 05 May 2020: eabc0473 DOI: 10.1126/science.abc0473 Abstract The rapid pace of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (COVID-19) presents challenges to the robust collection of population-scale data to address this global health crisis. We established the COronavirus Pandemic Epidemiology (COPE) consortium to bring together scientists with expertise in big data research and epidemiology to develop a COVID-19 Symptom Tracker mobile application that we launched in the UK on March 24, 2020 and the US on March 29, 2020 garnering more than 2.8 million users as of May 2, 2020. This mobile application offers data on risk factors, herald symptoms, clinical outcomes, and geographical hot spots. This initiative offers critical proof-of-concept for the repurposing of existing approaches to enable rapidly scalable epidemiologic data collection and analysis which is critical for a data-driven response to this public health challenge.
    37浏览量
    原文链接

  • 《JAMA，5月27日，Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-28
    • Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19 Daniel A. Goldstein, MD1,2; Mark J. Ratain, MD3; Leonard B. Saltz, MD4 Author Affiliations Article Information JAMA Oncol. Published online May 27, 2020. doi:10.1001/jamaoncol.2020.2493 The coronavirus disease 2019 (COVID-19) pandemic has shocked the world and caused a period of both economic and medical catastrophe. Two major challenges face the world of medical oncology. Oncologists need to reconsider all of their clinical practices to decrease the risk of exposure of their patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oncologists also need to consider that the world has changed considerably in economic terms. Now, more than ever, we need to assess whether our recommended therapies will cause financial hardship, on both an individual and a societal level. In this article we propose a solution related to the dosing of pembrolizumab that will maintain therapeutic outcomes, decrease detrimental financial effects of treatment, and decrease exposure risk to SARS-CoV-2.
    25浏览量
    原文链接